Clinical Trial Results: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating safety and immune response of an RSV vaccine in older adults (60+) and high-risk adults (50-59) with RSV-LRTD risk; results com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections
• Respiratory Syncytial Virus Lower Respiratory Tract Disease

Drugs mentioned

• GlaxoSmithKline RSV vaccine (investigational name not provided in snippet)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2026-06-23